Wenxin (Vincent) Xu, MD presents a potential biomarker (KIM-1) - Takeaways - MDSpire

Wenxin (Vincent) Xu, MD presents a potential biomarker (KIM-1)

Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.

  • February 26, 2025

Share

  • 1

    KIM-1 is being investigated as a potential blood test for detecting and monitoring kidney cancer.

  • 2

    The study analyzed samples from over 800 patients in the CheckMate 214 trial.

  • 3

    KIM-1 levels measured after 3 weeks of treatment can predict long-term outcomes in advanced renal cell carcinoma.

  • 4

    Patients with improved KIM-1 levels had a progression-free survival of 71 months compared to 4 months for those with increased levels.

  • 5

    Validation of KIM-1 could help identify patients who respond well to immunotherapy and optimize treatment strategies.

Original Source(s)

Wenxin (Vincent) Xu, MD presents a potential biomarker (KIM-1)

  • February 26, 2025

Related Content

Assessment of Venous Thrombus Characteristics in Renal Cell Carcinoma Patients Through Volumetric Computed Tomography First-Order Radiomic Features

Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group

Sesquiterpenoids influence IFIT protein family and LIMK1: potential effects on the tumor microenvironment and macrophage infiltration